Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung

By J. W. Lee, Xiaohui Fang, N. Gupta, V. Serikov, Michael A. Matthay. Proceedings of the National Academy of Sciences of the United States of America, 2009

652 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/21b4887e50860dec481f111f919691e479e52061

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael A. Matthay
2. R. Zemans

In Pulmonary and Respiratory Medicine

1. R. Zemans
2. Michael A. Matthay
3. N. Gupta
4. V. Serikov
5. S. Kourembanas

Citations in the corpus

• Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. (2015, background): “Treatment with allogeneic human MSCs or their CM administered 1 h following endotoxin-induced lung injury reduced extravascular lung water, improved lung endothelial barrier permeability, and restored alveolar fluid clearance (76).”
• Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL-37 (2010, methodology): “5A–5D), reflecting the immunomodulatory properties of MSCs [18–22].”
• The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment (2011, methodology): “Finally, our own work with a perfused ex vivo human lung preparation indicated that administration of MSCs 1 h after severe endotoxin-induced lung injury was effective in normalizing lung vascular and epithelial permeability to protein as well as reducing pulmonary edema and increasing the rate of a”